Drug intelligence / Profile preview

UFT + cisplatin + leucovorin

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

UFT + cisplatin + leucovorin is a chemotherapy combination regimen used primarily for treating advanced cancers. UFT is an oral fluoropyrimidine that combines tegafur (a prodrug of 5-fluorouracil) with uracil. When combined with cisplatin and leucovorin (folinic acid), this regimen has been studied in various cancer types including non-small-cell lung cancer, esophageal cancer, and gastric cancer. The combination aims to improve efficacy while maintaining a convenient outpatient administration schedule compared to regimens requiring protracted venous infusion.

Other names: EPUL

Targets

DPYD (Dihydropyrimidine dehydrogenase)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on UFT + cisplatin + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UFT + cisplatin + leucovorin.

Explore the full profile